Botox

Botox cosmetic is a prescription medicine injection to temporarily improve the look of both moderate and severe crows feet lines and frown lines between the eyebrows.

BEFORE*

sandra_front_before
sandra_side_before

AFTER*

sandra_front_after
sandra_side_after

Botox–Cosmetic

Longevity of 3-4 months, but when people come that often for approximately a year, the muscle forming the wrinkle atrophies, and thus they often can spread out 4-6 months.

Treatment Areas

  • Forehead
  • Frown or Glabellar Lines 11’s
  • Crows feet
  • Bunny or Nasalis Lines
  • Smokers lines
  • EyeBrow Lift
  • Dimpled Chin
  • Smile Lift or Corners of the mouth lift
  • Gummy Smile
  • Lower Eye Wrinkles
  • Jaw Reduction via Masseter Muscle injection
  • Turkey Neck

*Actual patients. Results may vary. Read our Safety Information and Disclaimer for more information.

Photos taken at maximum smile and at maximum frown before treatment with BOTOX® Cosmetic (onabotulinumtoxinA), and taken at maximum smile after treatment with BOTOX® Cosmetic at day 7, and taken at maximum frown after treatment with BOTOX® Cosmetic at day 7 and months 3 and 4.

Moderate to Severe Lateral Canthal Lines
In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ? 2-grade improvement from baseline in crow’s feet line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) for placebo, as assessed by both investigators and subjects.1

Moderate to Severe Glabellar Lines
In clinical trials at day 7, 74% (299/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 6% (8/132) in placebo, as assessed by investigators; at day 30, 80% (325/405) of patients demonstrated the same as compared to 3% (4/132) in placebo; at month 3, 48% (192/403) of patients demonstrated the same as compared to 2% (3/128) in placebo; at month 4, 25% (102/403) of patients demonstrated the same as compared to 2% (2/128) in placebo.1

In clinical trials at day 7, 82% (334/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 9% (12/132) in placebo, as evaluated by patients; at day 30, 89% (362/405) of patients assessed the same as compared to 7% (9/132) in placebo; at month 3, 63% (254/403) of patients assessed the same as compared to 3% (4/128) in placebo; at month 4, 39% (157/403) of patients assessed the same as compared to 1% (1/128) in placebo.1

1 BOTOX® Cosmetic Prescribing Information, February 2016.